Intangible Assets, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	May 04, 2021
Finite Lived Intangible Assets [Line Items]
Weighted-average useful life of intangible assets			6 years
Amortization expense of intangible assets	$ 300	$ 500	$ 600	$ 1,100
Research and development expenses	13,094	$ 20,646	27,179	$ 42,390
CDE IPR&D
Finite Lived Intangible Assets [Line Items]
Research and development expenses			100
Global Supply Chain Platform
Finite Lived Intangible Assets [Line Items]
Goodwill	26,600		26,600
Oncology Innovation Platform
Finite Lived Intangible Assets [Line Items]
Goodwill	$ 41,100		41,100
Kuur | Merger Agreement
Finite Lived Intangible Assets [Line Items]
Goodwill					$ 28,711
Hanmi Pharmaceuticals Co. Ltd. | Licensing Agreements
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired			$ 400
Acquired finite-lived intangible assets, amortization period			12 years 9 months
Gland Pharma Limited | Licensing Agreements
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired			$ 3,800
Acquired finite-lived intangible assets, amortization period			5 years
MAIA Pharmaceuticals, Inc | Licensing Agreements
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired			$ 4,000
Acquired finite-lived intangible assets, amortization period			7 years
Ingenus Pharmaceuticals, LLC | Licensing Agreements
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired			$ 3,000
Ingenus Pharmaceuticals, LLC | Licensing Agreements Amortized Over a Period of 5 years
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired			$ 2,000
Acquired finite-lived intangible assets, amortization period			5 years
Ingenus Pharmaceuticals, LLC | Licensing Agreements Amortized Over a Period of 3 years
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired			$ 1,000
Acquired finite-lived intangible assets, amortization period			3 years
Ingenus Pharmaceuticals, LLC | Licenses of Other Specialty Products
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired			$ 2,800